Original articleImmune checkpoint-mediated psoriasis: A multicenter European study of 115 patients from the European Network for Cutaneous Adverse Event to Oncologic Drugs (ENCADO) group
Section snippets
Patients and methods
This was a multicenter, retrospective study of psoriasis related to immunotherapy, conducted in the name of the European Network for Cutaneous Adverse Event to Oncologic Drugs (ENCADO) group. For the aims of the study, we used the databases of 9 oncodermatology units from Greece, France, Italy, Spain, and Argentina and searched for psoriasis cases developing through the treatment course with ICI until the end of December 2019. Inclusion criteria were patients developing psoriasis after
Results
European Network for Cutaneous Adverse Event to Oncologic Drugs group members provided data of 115 patients with anti–PD-1/PD-L1–induced psoriasis that were included in the study. The mean (SD) follow-up period after psoriasis diagnosis was 9.3 (7.09) months.
Demographic characteristics of the study group are listed in Table I. Thirty-three of 115 (30.8%) patients had a personal history of psoriasis; in 20 out of 33 of them, the disease was active and clinically apparent upon ICI initiation.
Discussion
Psoriatic lesions have been reported in various case series of ICI treatment.7, 8, 9, 10, 11, 12 Several studies report that the majority of these patients are complicated with psoriasis on the setting of exacerbation of a pre-existing condition.10,13, 14, 15 We present, to our knowledge, the largest series to date of patients with cancer treated with ICIs, complicated with psoriasis. According to our analysis, 70% of the cases were affected by psoriasis de novo with unique disease features.
Conflicts of interest
None disclosed.
References (30)
- et al.
Cutaneous adverse effects of the immune checkpoint inhibitors
Curr Probl Cancer
(2017) - et al.
RECIST 1.1- Update and clarification: from the RECIST committee
Eur J Cancer
(2016) - et al.
Anti-PD1/PDL1 induced psoriasis
Curr Probl Cancer
(2017) - et al.
Development of psoriatic arthritis during nivolumab therapy for metastatic non-small cell lung cancer, clinical outcome analysis and review of the literature
Lung Cancer
(2017) - et al.
Inflammatory eruptions associated with immune checkpoint inhibitor therapy: a single-institution retrospective analysis with stratification of reaction by toxicity and implications for management
J Am Acad Dermatol
(2019) - et al.
Characterization of dermatitis after PD-1/PD-L1 inhibitor therapy and association with multiple oncologic outcomes: a retrospective case-control study
J Am Acad Dermatol
(2018) - et al.
Survival and prognosis of individuals receiving programmed cell death 1 inhibitor with and without immunology cutaneous adverse events
J Am Acad Dermatol
(2020) - et al.
Successful treatment of psoriasis induced by immune checkpoint inhibitors with apremilast
Eur J Cancer
(2019) - et al.
An immunotherapy survivor population: health-related quality of life and toxicity in patients with metastatic melanoma treated with immune checkpoint inhibitors
Support Care Cancer
(2020) - et al.
Association of checkpoint inhibitor-induced toxic effects with shared cancer and tissue antigens in non-small cell lung cancer
JAMA Oncol
(2019)
Dermatologic complications of anti-PD-1/PDL1immune checkpoint antibodies
Curr Opin Oncol
Dermatologic reactions to immune checkpoint inhibitors: skin toxicity and immunotherapy
Am J Clin Dermatol
Anti-PD1-induced psoriasis. A study of 21 patients
J Eur Acad Dermatol
Development of de novo psoriasis during nivolumab therapy in a patient with small cell lung cancer
J Oncol Pharm Pract
New onset psoriasis during nivolumab treatment for lung cancer
J Dermatol
Cited by (43)
Immune Checkpoint Inhibitor-Induced Psoriasis: Diagnosis, Management, and a Review of Cases
2024, Dermatologic ClinicsPsoriasis de novo or exacerbation by PD-1 checkpoint inhibitors
2024, Anais Brasileiros de DermatologiaImmunotherapy for keratinocyte cancers. Part I: Immune-related epidemiology, risk factors, pathogenesis, and immunotherapy management of keratinocyte cancers
2023, Journal of the American Academy of DermatologyImmunotherapy for keratinocyte cancers. Part II: Identification and management of cutaneous side effects of immunotherapy treatments
2023, Journal of the American Academy of Dermatology
Funding sources: None.
IRB approval status: Not applicable.